Compare Marqeta Inc (MQ) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marqeta Inc vs Tango Therapeutics Inc. — how do they compare? Marqeta Inc trades at $18.39 (market cap $1.93B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Tango Therapeutics Inc. is the larger of the two by market cap, and Marqeta Inc is more actively traded (915,027 versus 9,619,106). Which is the better fit depends on your goals — on Pluang, investors hold Marqeta Inc for 44 Days and Tango Therapeutics Inc. for 0 Days on average.
| MQ | TNGX | |
|---|---|---|
Market Cap | $1.93B | $3.75B |
Volume | 915,027 | 9,619,106 |
Sector | Technology | Health |
52-Week High | $20.32 | $32.90 |
52-Week Low | $15.04 | $7.50 |
Typical Hold Time | 44 Days | 0 Days |
Enterprise Value | $1.25B | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $18.18, down 0.6% on the day, with a bullish technical signal from moving averages. The company reported three consecutive quarterly earnings beats, with Q2 2026 showing 17% net revenue growth and GAAP profitability. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight strategic expansion. Cash flow turned positive in 2025 at $86.42M, a significant improvement from prior years' losses.
Outlook is mixed: strong revenue growth and product initiatives support upside, but high P/E of 206.22 and thin net margin of 1.53% pose valuation risks. Analyst consensus is cautious with a $11.38 price target, well below current levels. Key risks include contract renewals in Q3 2026 and competitive pressures in fintech.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
